These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

450 related items for PubMed ID: 35805109

  • 1. GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight.
    Monti G, Gomes Moreira D, Richner M, Mutsaers HAM, Ferreira N, Jan A.
    Cells; 2022 Jun 25; 11(13):. PubMed ID: 35805109
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Beyond insulin: The Intriguing role of GLP-1 in Parkinson's disease.
    Verma A, Goyal A.
    Eur J Pharmacol; 2024 Nov 05; 982():176936. PubMed ID: 39182542
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
    Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST.
    CNS Drugs; 2019 Mar 05; 33(3):209-223. PubMed ID: 30511349
    [Abstract] [Full Text] [Related]

  • 8. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Sheng Li Xue Bao; 2014 Oct 25; 66(5):497-510. PubMed ID: 25331995
    [Abstract] [Full Text] [Related]

  • 9. [Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?].
    García-Casares N, García-Arnés JA, Gómez-Huelgas R, Valdivielso-Felices P, García-Arias C, González-Santos P.
    Rev Neurol; 2014 Dec 01; 59(11):517-24. PubMed ID: 25418147
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic potential of spinal GLP-1 receptor signaling.
    Zhang D, Lv G.
    Peptides; 2018 Mar 01; 101():89-94. PubMed ID: 29329976
    [Abstract] [Full Text] [Related]

  • 11. Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection.
    Hölscher C.
    CNS Drugs; 2012 Oct 01; 26(10):871-82. PubMed ID: 22938097
    [Abstract] [Full Text] [Related]

  • 12. Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease.
    Verma A, Chaudhary S, Solanki K, Goyal A, Yadav HN.
    Chem Biol Drug Des; 2024 Jan 01; 103(1):e14426. PubMed ID: 38230775
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
    Hölscher C.
    Neuropharmacology; 2024 Aug 01; 253():109952. PubMed ID: 38677445
    [Abstract] [Full Text] [Related]

  • 14. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B, Dinda M, Kulsi G, Chakraborty A, Dinda S.
    Eur J Med Chem; 2019 May 01; 169():185-199. PubMed ID: 30877973
    [Abstract] [Full Text] [Related]

  • 15. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
    Wang XH, Yang W, Qi JS.
    Sheng Li Xue Bao; 2010 Oct 25; 62(5):398-406. PubMed ID: 20945041
    [Abstract] [Full Text] [Related]

  • 16. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
    Athauda D, Foltynie T.
    Neuropharmacology; 2018 Jul 01; 136(Pt B):260-270. PubMed ID: 28927992
    [Abstract] [Full Text] [Related]

  • 17. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde M, Hölscher C.
    J Parkinsons Dis; 2020 Jul 01; 10(2):523-542. PubMed ID: 31958096
    [Abstract] [Full Text] [Related]

  • 18. A novel dual-glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist is neuroprotective in transient focal cerebral ischemia in the rat.
    Han L, Hölscher C, Xue GF, Li G, Li D.
    Neuroreport; 2016 Jan 06; 27(1):23-32. PubMed ID: 26555034
    [Abstract] [Full Text] [Related]

  • 19. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
    Calsolaro V, Edison P.
    CNS Drugs; 2015 Dec 06; 29(12):1023-39. PubMed ID: 26666230
    [Abstract] [Full Text] [Related]

  • 20. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
    Zhang ZQ, Hölscher C.
    Peptides; 2020 Mar 06; 125():170184. PubMed ID: 31705913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.